Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

th pegylated interferon and ribavirin. The actual timing for the initiation of Phase II studies may depend on a number of factors, including FDA review timelines, the timing of any potential transaction around ANA598 or ANA773, available cash resources and funding activities, and the engagement of clinical sites.

14 Day Healthy Volunteer Study

Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received ANA598 or placebo on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, although three subjects receiving ANA598 (two in the 800 mg once-daily cohort and one in the 600 mg bid cohort) developed grade 2 rash and discontinued treatment after either six or seven days of consecutive dosing. There were no other instances of rash in this or any other study of ANA598. Data receipt and analysis from this study is continuing, and the Company expects to present the results at a clinical conference later this year. The Company believes the results of this study, combined with the results of the Phase Ib study in HCV patients, contribute to the attractive profile of ANA598 as an antiviral likely to be active in long-term studies in combination with pegylated interferon and ribavirin, and help position the program to be ready for Phase II in mid-2009.

Long-term Toxicology Studies

In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598, of 26 weeks duration in rats a
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
... Medical Systems, a global developer of high-end ultrasound systems, ... number of clinical applications and ranked first or second ... KLAS  "Ultrasound 2011: Innovation on the Move" report. ... monitoring and reporting the performance of information technology and ...
... Suneva Medical, a privately-held aesthetic medical device ... aesthetics injectable business with approval from Health Canada ... dermal filler for nasolabial folds or smile line ... long-lasting treatment, Bellafill provides physicians the opportunity to ...
Cached Medicine Technology:ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 2ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 3Suneva Medical Announces Canadian Approval of Bellafill™ 2
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
(Date:9/18/2014)... In ecology, disease tolerance is ... and nail, but rather tolerate it to live (and survive) better ... the disease only progresses very slowly if at all ... Regoes, a senior scientist at ETH Zurich,s Institute of Theoretical Biology, ... whether there are infected people who are more tolerant of the ...
(Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
(Date:9/18/2014)... Pittsburgh, PA (PRWEB) September 18, 2014 ... oncologists from Allegheny Health Network has documented ... undergo both surgical removal of the tumors along with ... annual meeting of ASTRO (American Society for ... radiosurgery (SRS) uses numerous precisely focused radiation beams to ...
Breaking Medicine News(10 mins):Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... , ATLANTA, Aug. 6 ... the launch of an Atlanta-based program aimed at improving ... Emory University,s Latino Diabetes Education Program and the Johnson ... diabetes education in Hispanic and African American populations and ...
... , , MOUNTAIN ... MAPP ) announced today the pricing of its previously announced public ... offering price of $9.70 per share. Net proceeds, after estimated underwriting ... MAP Pharmaceuticals has granted the underwriters of the offering a ...
... , , , ... Inc. (OTC Bulletin Board: CCEL), one of the largest and most ... proliferative ability of stem cells found in menstrual blood (known as ... Dalian, China. Data from an in vitro study show that MenSCs ...
... Puerto Ricans, Mexicans, study finds , WEDNESDAY, Aug. 5 (HealthDay ... the good life comes at a price: A new study ... , Living the American lifestyle is probably to blame, say ... , Of three Hispanic subgroups they studied -- Puerto Ricans, ...
... , ST. LOUIS, Aug. 6 ... improvement and cost savings results of the IMI program at ... Association (AHA) Leadership Summit. Kirk Mathews, CEO of IMI, and ... average three-month-trend results of $1,500 Cost-per-Case reduction as well as ...
... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... launch of three MedCounselor consumer drug information modules for pharmacies ... how to take medications safely, assists in identifying unknown tablets ... are indispensable in helping to increase consumer compliance to their ...
Cached Medicine News:Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 2Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 3Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 4Health News:MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock 2Health News:MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock 3Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 2Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 3Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 4Health News:Living in U.S. May Raise Hispanics' Cancer Risk 2Health News:Living in U.S. May Raise Hispanics' Cancer Risk 3Health News:Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 3
Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
Delicate strong curved serrated tips. Serrated handle with dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
Medicine Products: